Your browser doesn't support javascript.
loading
Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor.
Fontana, Elisa; Torga, Gonzalo; Fostea, Raluca; Cleator, Susan; Wasserman, Ernesto; Murat, Anastasia; Arkenau, Hendrik-Tobias.
Afiliação
  • Fontana E; Drug Development Unit, Sarah Cannon Research Institute UK, Marylebone, London, United Kingdom.
  • Torga G; Drug Development Unit, Sarah Cannon Research Institute UK, Marylebone, London, United Kingdom.
  • Fostea R; Drug Development Unit, Sarah Cannon Research Institute UK, Marylebone, London, United Kingdom.
  • Cleator S; Oncology Department, Imperial NHS Healthcare, Charing Cross Hospital, London, United Kingdom.
  • Wasserman E; Merus NV, Utrecht, the Netherlands.
  • Murat A; Merus NV, Utrecht, the Netherlands.
  • Arkenau HT; Drug Development Unit, Sarah Cannon Research Institute UK, Marylebone, London, United Kingdom.
JCO Precis Oncol ; 6: e2100446, 2022 08.
Article em En | MEDLINE | ID: mdl-35977350
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Idioma: En Ano de publicação: 2022 Tipo de documento: Article